LM-299 is a bispecific antibody targeting PD-1 and VEGF with anti-tumor activity. The dual binding activity of LM-299 is achieved through the effective binding of its Fab-terminal anti-VEGF-A antibody to human VEGF-A, as well as the blocking effect of its Fc-terminal anti- PD-1 antibody on the PD-1/PD-L1 pathway. LM-299 binds to and modulates PD-1 and VEGF. LM-299 can be used in studies related to advanced malignant tumors, advanced solid tumors, and advanced non-small cell lung cancer [1] [2].
In Vitro, LM-299 binds to and regulates PD-1 and VEGF[1].
References:
[1]. Li J, et al. Abstract CT057: Preliminary results from the first-in-human study of MK-2010, a PD-1×VEGF bispecific antibody. Cancer Res. 2026;86 (8_Suppl):CT057.
[2]. McCartney F. November Industry News. Therapeutic Delivery. 2025;16(3):199-204.
In Vitro, LM-299 binds to and regulates PD-1 and VEGF[1].
References:
[1]. Li J, et al. Abstract CT057: Preliminary results from the first-in-human study of MK-2010, a PD-1×VEGF bispecific antibody. Cancer Res. 2026;86 (8_Suppl):CT057.
[2]. McCartney F. November Industry News. Therapeutic Delivery. 2025;16(3):199-204.